Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
LGVN
#4545
Longeveron Inc. - Class A Common stock
0.6
9
USD
-0.07%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-6.76%
Monthly Change
0.00%
6 month change
+20.78%
Year Change
+20.78%
Previous Close
0.7
4
Open
0.6
9
Low
0.6
9
High
0.6
9
Volume
1
Markets
US Stock Market
Healthcare
Biotechnology
LGVN
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
2024
Current report, Q3 FY2024
2024.07.03
Longeveron Inc. current report, Q3 FY2024
8-K
Quarterly report, Q2 FY2024
2024.08.14
Longeveron Inc. quarterly report, Q2 FY2024
10-Q
Current report, Q2 FY2024
2024.06.18
Longeveron Inc. current report, Q2 FY2024
8-K
1
2
3
4
5
News
Longeveron Inc. (LGVN) Shareholder/Analyst Call Prepared Remarks Transcript
Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript
Longeveron closes $15 million financing, extends runway to 4Q26
Longeveron secures $15M financing, eyes $15M more on trial results
Longeveron publishes phase 2b stem cell trial results in journal
Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results
Longeveron receives Japanese patent for stem cell potency assay methods
Longeveron prepares for pivotal HLHS therapy data with FDA meeting
Longeveron receives patent for stem cell therapy targeting female sexual dysfunction
Longeveron executives to speak at CVCT Forum on cell therapy trials
Longeveron receives Canadian patent for stem cell therapy